Latest Breaking News On - Tumor programs presented - Page 1 : comparemela.com

– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Phase 3 DeFi Trial Evaluating. | May 3, 2023

United statesSaqib islamSamantha hilson sandlerTrademark officeSpringworks therapeutics incDevelopment rd expensesEuropean medicines agencyAmerican association for cancer research annual meetingDrug administrationAmerican association for cancer researchDesmoid tumors acceptedGranted priority reviewDate setDesmoid tumors publishedNew england journalEncouraging clinical data